Endocrine Abstracts

Introduction: In our previous studies we found that the combination of 13-cis retinoic acid (13cRA) and lovastatin significantly reduced tumour growth in a mouse phaeochromocytoma allograft model, with the lowest microvessel density in the combination-treated tumours. We have now investigated the effect of 13cRA plus lovastatin on neuroendocrine (BON1, H727) and non-endocrine tumour (HepG2, Huh7) cell viability and signalling pathways (EGFR, AKT, ERK, p70S6K) to eluci...

Due to limited treatment options the prognosis of patients with advanced hepatocellular cancer (HCC) has remained poor. We therefore examined the feasibility of radioiodine therapy of HCC after human sodium iodide symporter (hNIS) gene transfer, using the tumor-specific alpha-fetoprotein (AFP) promoter for transcriptional targeting. For this purpose NIS gene transfer was performed in vivo in human HCC cell (HepG2) xenografts, using replication-deficient adenoviral vecto...

We have recently demonstrated induction of tumor-selective accumulation and therapeutic efficacy of radioiodine in neuroblastoma tumors after systemic non-viral polyplex-mediated sodium-iodide-symporter (NIS) gene delivery.In the current study, we evaluated the efficacy of novel synthetic nanoparticle vectors based on linear polyethylenimine (LPEI), shielded by polyethylene glycol (PEG), and coupled with the synthetic peptide GE11 as an epidermal growth ...

In its early stages, malignant melanoma can be cured by surgical resection, but once it has progressed to the metastatic stage it does not respond to current therapies. Therefore, the development of novel treatment strategies, such as gene therapy, is urgently needed. To investigate an alternative approach, we examined the feasibility of NIS-mediated radionuclide therapy (131I, 188Re) of malignant melanoma following human sodium iodide symporter (NIS) gen...